A U.S. judge on Monday rejected Bristol Myers Squibb’s bid to dismiss a $6.7 billion lawsuit claiming it cheated shareholders of the former Celgene by delaying federal approval for three drugs, including the cancer treatment Breyanzi, by specified deadlines.
While dismissing some claims, U.S. District Judge Jesse Furman in Manhattan said the plaintiff UMB Bank may pursue some claims on behalf of the shareholders, including for breach of contract.
(Reporting by Stempel in New York; Editing by Chris Reese)
Copyright 2025 Reuters. Click for restrictions.
Was this article valuable?
Here are more articles you may enjoy.
Tesla Drivers Are Buying Escape Tools and Cars to Avoid Getting Trapped Inside 
Pacific Northwest Braces for Even More Flooding Rain This Week 
Marijuana’s Move to Schedule III: What it Really Means for Cannabis Insurance 
‘Dream Is in Sight:’ Chamber, Reinsurers, Insurers Urge Florida to Stay the Course 
Want to stay up to date?
Get the latest insurance news
sent straight to your inbox.